The healthcare technology company will partner with AbbVie in an aim to examine data collected from MC10’s BioStamp nPoint system as potential insights into multiple sclerosis (MS) clinical studies.
Ben Schlatka, CEO of MC10 told us that the BioStamp nPoint system is a wearable that continuously collects physiological data outside of the clinic. This system, “enables a more complete picture of a subject’s health throughout a clinical trial,” he added.
The wearable has 44 endpoints generated by MC10’s algorithms and also has capabilities to collect raw sensor data from any location on the body which Schlatka said can enable the exploration of new digital biomarkers, which according to Schlatka, can provide “invaluable data related to treatment effect and quality of life.”
BioStamp nPoint is also capable of remote data collection so subjects can apply included sensors, complete daily prescribed activities, and log patient-reported outcomes while the wearable automatically uploads its collected data for analysis by the sponsor.
Schlatka told us that insights gained from this partnership can be applicable for MS trials as neurodegenerative diseases often result in a progressive loss of motor control. “Passive, continuous data collection allows for the measurement of motor control and quality of life metrics such as sleep duration and actigraphy in more natural settings,” he added.